Antivascular therapy for epithelial ovarian cancer
FP Duhoux, JP Machiels - Journal of oncology, 2010 - Wiley Online Library
Ovarian cancer is the fifth largest cancer killer in women. Improved understanding of the
molecular pathways implicated in the pathogenesis of ovarian cancer has led to the …
molecular pathways implicated in the pathogenesis of ovarian cancer has led to the …
Angiogenesis as a strategic target for ovarian cancer therapy
WA Spannuth, AK Sood, RL Coleman - Nature Clinical Practice …, 2008 - nature.com
Angiogenesis is a complex and highly regulated process that is crucial for tumor growth and
metastasis. Insights into the molecular mechanisms of tumor angiogenesis have led to the …
metastasis. Insights into the molecular mechanisms of tumor angiogenesis have led to the …
New ways to successfully target tumor vasculature in ovarian cancer
X Yang, F Shen, W Hu, RL Coleman… - Current Opinion in …, 2015 - journals.lww.com
When to start and end antiangiogenesis therapy and the choice of optimal treatment
combinations remain controversial. Further evaluation of personalized novel angiogenesis …
combinations remain controversial. Further evaluation of personalized novel angiogenesis …
State of the science: emerging therapeutic strategies for targeting angiogenesis in ovarian cancer
W Graybill, AK Sood, BJ Monk… - Gynecologic …, 2015 - gynecologiconcology-online.net
Ovarian cancer is clinically characterized by advanced stage at presentation, transient
chemosensitivity, and stagnant long-term survivorship rates despite a broadening portfolio of …
chemosensitivity, and stagnant long-term survivorship rates despite a broadening portfolio of …
Development of antiangiogenic agents for ovarian cancer
FJ Collinson, GD Hall, TJ Perren… - Expert review of …, 2008 - Taylor & Francis
Epithelial ovarian cancer (EOC) remains a major source of cancer morbidity and mortality,
despite advances in surgical and chemotherapeutic management. The molecular pathways …
despite advances in surgical and chemotherapeutic management. The molecular pathways …
Anti-angiogenic agents in ovarian cancer: dawn of a new era?
J Liu, UA Matulonis - Current oncology reports, 2011 - Springer
Epithelial ovarian cancer is a leading cause of cancer-related death for women both in the
United States and worldwide, and the effectiveness of cytotoxic chemotherapy has …
United States and worldwide, and the effectiveness of cytotoxic chemotherapy has …
Targeting angiogenesis in ovarian cancer
J Schmitt, D Matei - Cancer treatment reviews, 2012 - Elsevier
Results of standard chemotherapy in ovarian cancer are hampered by the development of
drug resistance leading to disease recurrence. This prompted interest in the development of …
drug resistance leading to disease recurrence. This prompted interest in the development of …
Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition
L Martin, R Schilder - Journal of clinical oncology, 2007 - ascopubs.org
Despite an aggressive approach of surgical cytoreduction and adjuvant combination
chemotherapy, ovarian cancer mortality remains a significant problem. We are entering a …
chemotherapy, ovarian cancer mortality remains a significant problem. We are entering a …
Turning promise into progress for antiangiogenic agents in epithelial ovarian cancer
ARM van der Bilt, EGE de Vries, S de Jong… - Critical reviews in …, 2012 - Elsevier
Despite efforts to improve chemotherapeutic efficacy in epithelial ovarian cancer, outcome
for patients with advanced disease has remained unchanged since the introduction of …
for patients with advanced disease has remained unchanged since the introduction of …
Targeted therapy of ovarian cancer with angiogenesis inhibitors
P Duan, L Fan, Q Gao, B Mukunda Silwal… - Current Drug …, 2017 - ingentaconnect.com
Specific blocking of interactions between ligands and receptors along the angiogenic
pathways represents an effective approach for enhancing the efficacy as well as reducing …
pathways represents an effective approach for enhancing the efficacy as well as reducing …